HOME
CAREERS
CONTACT US
KOREAN
ENGLISH
KR
EN
Toggle navigation
COMPANY
ABOUT US
KEY MEMBERS
HISTORY
BOARD OF DIRECTORS
SCIENTIFIC ADVISORY BOARD
SCIENCE
NT-I7
NeoBase
NT2020
NT3020
NT4010
NT5010
PIPELINE
Clinical
R&D
COLLABORATION
INVESTORS
NOTICE
PRESENTATION
GENERAL MEETING
OF STOCKHOLDERS
INDEPENDENT
AUDITOR'S REPORT
CONTACT IR
MEDIA
NEWS
VIDEO SOURCE
ESG
OVERVIEW
ENVIRONMENTAL
SOCIAL
GOVERNANCE
NEWS
HOME
MEDIA
NEWS
NEWS
Total
101
91
FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech’s NT-I7 for Advanced Pancreatic Cancer Treatment
2024-01-30
90
Phase II Study Expansion Investigating NeoimmuneTech’s NT-I7 in Head and Neck Cancer
2024-01-29
89
NeoImmuneTech Welcomes a New President for its development and business
2024-01-15
88
QUARTERLY UPDATE (Q4 2023)
2024-01-04
87
NeoImmuneTech and Imugene enter into strategic research collaboration to improve cancer treatments
2023-12-12
86
FDA Grants Orphan Drug Designation to NeoImmuneTech’s NT-I7 for the Treatment of Acute Radiation Syndrome
2023-11-20
85
QUARTERLY UPDATE (Q3 2023)
2023-10-26
84
NeoImmuneTech to Present New Advances on NT-I7 (efineptakin alfa) at 2023 SITC Annual Meeting
2023-10-04
83
NeoImmuneTech Welcomes Two New Members to its Scientific Advisory Board
2023-07-26
82
QUARTERLY UPDATE (Q2 2023)
2023-07-05
1
2
3
4
5
>
>>
Search